Nona Baker, who was first diagnosed with a blood cancer in 1991, shares her experience with polycythemia vera. Nona Baker, ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., December 06, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from ...

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the oral presentation of positive results ...

CURE spoke with Dr. Marina Kremyanskaya about the treatment landscape for patients with polycythemia vera.

Rusfertide maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks in the VERIFY study. Patients switching from placebo to rusfertide showed rapid ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in ...

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well ...

Evaluation in 18 patients with polycythemia vera showed hematocrit control below 45%, accompanied by a "dramatic decrease in ...

Patients with polycythemia vera (PV) taking the investigational therapy rusfertide were able to largely maintain hematocrit control and avoid the need for phlebotomy over 52 weeks, according to ...

Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, ...